For example, thecytokine release syndrome (CRS) that accompanies chimeric antigen receptor (CAR-)T cell therapies typically arises within 1 week of administration (even earlier with concomitant high-dose IL-2) and constitutes a clinicalsyndrome that admits multivariate monitoring on numerous quantitative clinical and laboratory measures29. This evidence concerns the gene IL2 and congenital rubella syndrome.